By Gilang Cahya 
London, UK – Researchers at the Francis Crick Institute, in a significant collaboration with Revolution Medicines, have unveiled compelling preclinical findings demonstrating a novel therapeutic approach that successfully enables immunotherapies to target previously non-responsive lung tumours in mice. This pioneering research, published in the esteemed journal Nature Communications, suggests that a multi-pronged attack on cancer cells, simultaneously addressing tumour vulnerabilities from different angles, can significantly enhance treatment efficacy and potentially overcome the challenge of immunotherapy resistance. The study meticulously details how a combination of targeted inhibitors, alongside a potent immune checkpoint blockade, achieved remarkable tumour shrinkage and even complete eradication in a substantial portion of the mouse models tested.
The Challenge of Immunotherapy Resistance in Lung Cancer
Lung cancer remains a leading cause of cancer-related deaths globally, and while immunotherapies have revolutionized treatment paradigms for many patients, a significant proportion of individuals do not experience durable responses. This resistance is often attributed to the complex interplay between cancer cells and the immune system. Tumours can develop sophisticated mechanisms to evade immune surveillance, including suppressing the activity of immune cells or creating an immunosuppressive microenvironment. For "immune cold" tumours, characterized by a lack of immune cell infiltration, conventional immunotherapies have historically proven ineffective. The quest for strategies that can sensitize these resistant tumours to immune attack has been a paramount focus in oncology research.
Unpacking the Triple Combination Therapy
The cornerstone of this groundbreaking study lies in the strategic combination of three distinct therapeutic agents, each designed to address a critical aspect of tumour biology and immune evasion. The research team focused on two key molecular targets within cancer cells and a crucial mechanism by which cancer cells shield themselves from the immune system.
1. Targeting KRAS G12C Mutations: The study employed a newly identified inhibitor specifically designed to target the KRAS G12C mutation. This mutation is prevalent in a significant subset of non-small cell lung cancers (NSCLC), a common form of lung cancer. For years, KRAS mutations were considered "undruggable" due to the protein’s complex structure. The development of selective KRAS G12C inhibitors represents a major breakthrough, offering a direct means to inhibit the uncontrolled proliferation driven by this mutation. By blocking the aberrant signaling pathway initiated by the mutated KRAS protein, this inhibitor aims to halt cancer cell growth and division.
2. Inhibiting SHP2: A Dual Role in Cancer and Immunity: The second component of the combination therapy involved a compound that blocks the activity of SHP2 (Src homology 2 domain-containing phosphatase 2). SHP2 is a protein tyrosine phosphatase that plays a multifaceted role in cellular signaling. In cancer, SHP2 can promote tumour growth and survival by activating various oncogenic pathways, including those downstream of receptor tyrosine kinases. Crucially, SHP2 also plays a role in regulating immune responses. Inhibiting SHP2 can not only directly impact cancer cells but also modulate the tumour microenvironment in a way that is conducive to immune activation. This dual action makes SHP2 inhibition a compelling strategy in combination therapies.
3. Unleashing the Immune System with Immune Checkpoint Inhibitors: The third and arguably most critical component of this regimen is an immune checkpoint inhibitor. These drugs work by blocking proteins on immune cells or cancer cells that act as "brakes" on the immune system. In healthy individuals, immune checkpoints are essential for preventing autoimmune reactions. However, cancer cells often exploit these checkpoints to evade immune destruction. By blocking these inhibitory signals, immune checkpoint inhibitors "release the brakes," allowing T-cells and other immune components to recognize and attack cancer cells more effectively.
A Chronology of Discovery and Testing
The research leading to this significant publication can be traced back to years of fundamental research into cancer genetics and immunology. The development of KRAS G12C inhibitors, a process that has spanned over a decade with contributions from numerous research institutions and pharmaceutical companies, has been a significant scientific achievement. Revolution Medicines, a key partner in this study, has been at the forefront of developing novel targeted therapies, including SHP2 inhibitors.
The collaboration between the Francis Crick Institute, a world-leading biomedical research centre, and Revolution Medicines brought together expertise in molecular biology, drug discovery, and preclinical cancer models. The decision to investigate the synergistic potential of combining a KRAS G12C inhibitor, a SHP2 inhibitor, and an immune checkpoint inhibitor was driven by a growing understanding of the intricate crosstalk between oncogenic signaling pathways and the host immune system.
The experimental design involved carefully selected mouse models of lung cancer. These models were engineered to mimic key aspects of human lung cancer, including the presence of specific genetic mutations and varying degrees of immune responsiveness. The preclinical trials were conducted systematically, with researchers meticulously evaluating tumour growth, immune cell infiltration, and overall survival in response to the monotherapies and various combinations. The most promising results emerged from the triplet combination, leading to the detailed reporting of these findings in Nature Communications.
Supporting Data: Quantifying the Therapeutic Impact
The Nature Communications publication provides detailed quantitative data that underscores the efficacy of the triple combination therapy. While specific numerical values can vary between experimental cohorts, the general trend observed was highly encouraging:
- Tumour Regression: In mice with functional immune systems, the triplet combination therapy led to significant tumour regression. This was characterized by a marked reduction in tumour volume and mass compared to control groups receiving single agents or other combinations.
- Complete Eradication: In a notable proportion of mice, the combination therapy resulted in the complete eradication of tumours. This outcome signifies a complete pathological response, where no detectable tumour cells remain after treatment.
- Enhanced Immune Response: Post-treatment analysis revealed a significant increase in immune cell infiltration within the tumour microenvironment. Specifically, researchers observed a greater presence of cytotoxic T-cells, which are crucial for directly killing cancer cells. This suggests that the combination therapy effectively sensitized the tumours to immune attack.
- Reduced Recurrence: Crucially, mice that achieved tumour eradication also demonstrated enhanced resistance to cancer recurrence. This indicates that the therapy may have established a form of immunological memory, priming the immune system to recognize and eliminate any nascent cancer cells.
- "Immune Cold" Tumour Sensitization: The most striking finding was the impact on "immune cold" tumours. These tumours, which typically show minimal response to immune checkpoint inhibitors alone, became significantly more susceptible to immunotherapy when pre-treated with the KRAS G12C and SHP2 inhibitors. This suggests that the targeted inhibitors create a more permissive environment for immune cells to infiltrate and exert their anti-tumour effects.
Official Statements and Expert Perspectives
The researchers involved in this study have expressed considerable optimism regarding the implications of their findings.
Julian Downward, Principal Group Leader of the Oncogene Biology Laboratory at the Crick and co-senior author, stated, "Blocking genes like KRAS in lung cancer has led to some exciting new developments, but we still see problems with resistance. We’ve now been able to report partial or complete eradication of tumours in mice by combining KRAS and SHP2 inhibitors with immunotherapy. We also showed that this combination therapy allows ‘immune cold’ tumours to respond to the body’s own defences." This statement highlights the dual success of the therapy: achieving potent anti-tumour effects and overcoming a major hurdle in cancer treatment – resistance to immunotherapy, particularly in tumours that are less amenable to immune attack.
Panos Anastasiou, PhD student in the Oncogene Biology Laboratory at the Crick and first author of the study, elaborated on the significance of the multi-targeted approach. "Our work stresses the importance of targeting tumours from all angles, especially ones that don’t respond easily to treatment. It will be critical to see if the combination of inhibitors works in the same way in humans." This sentiment emphasizes the translational potential of the research and the need for further investigation in human clinical trials. Anastasiou’s involvement, supported by a broad array of scientific teams at the Crick, including Experimental Histopathology, Bioinformatics and Biostatistics, Genomics, Scientific Computing, Flow Cytometry, Cell Services, and Biological Resources, underscores the collaborative and multidisciplinary nature of this research.
While direct statements from Revolution Medicines were not included in the original source material, their involvement as a funding partner and developer of key compounds suggests their keen interest in the preclinical success of this combination. It is reasonable to infer that the company views these findings as highly promising for the future development of their therapeutic agents in combination settings.
Broader Impact and Future Implications
The implications of this research extend beyond the immediate context of lung cancer. The principles demonstrated – simultaneously targeting oncogenic signaling pathways and modulating the tumour microenvironment to enhance immune response – could be applicable to a wide range of cancer types that exhibit similar challenges with resistance to current therapies.
Potential for Overcoming Resistance Across Cancers: Many cancers are driven by mutations in oncogenes like KRAS, and resistance to immunotherapy is a universal challenge. This triple combination strategy offers a conceptual framework for developing more effective treatments for various malignancies.
Personalized Medicine Approaches: As our understanding of tumour heterogeneity and individual immune profiles grows, combination therapies like this could be tailored to specific patient populations based on their genetic makeup and the immunological landscape of their tumours.
Accelerated Clinical Development: Given the success in preclinical models, it is highly probable that this combination therapy will be evaluated in human clinical trials in the near future. The transition from mouse models to human patients is a critical step, and researchers will be closely monitoring for similar efficacy and safety profiles.
Addressing Potential Side Effects: A crucial aspect of combining multiple therapeutic agents is the potential for cumulative or synergistic toxicities. Future research will undoubtedly focus on understanding and mitigating any adverse side effects associated with this triplet regimen to ensure patient safety and tolerability in clinical settings. The development of biomarkers to predict response and identify patients most likely to benefit will also be a key area of investigation.
The collaborative research agreement between the Francis Crick Institute and Revolution Medicines, supported by additional funding from the European Union and the Wellcome Trust, highlights the significant investment and global effort dedicated to tackling complex diseases like cancer. This study represents a significant stride forward in the ongoing battle against cancer, offering renewed hope for patients who currently have limited treatment options. The successful translation of these preclinical findings into effective human therapies could mark a new era in cancer treatment, characterized by more potent, multi-targeted, and ultimately, more successful interventions.